Overview

To Evaluate the Efficacy and Safety Aliviador Compared to Gelol in Patients With Contusions, Sprains, Trauma and Muscle Injury.

Status:
Unknown status
Trial end date:
2010-08-01
Target enrollment:
0
Participant gender:
All
Summary
Multicenter, randomized, double-blind trial, to evaluate the efficacy and safety Aliviador compared to Gelol in the relief of signs and symptoms in patients with contusions, sprains, trauma and muscle injury start with less than 24 hours or patients of myalgia, myofascial pain and tendinitis.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Laboratorio Brasileiro de Biologia
Criteria
Inclusion Criteria:

- Patients of both sexes, of any race, aged over 12 years.

- Ability to read, understand and sign the IC, in the case of minors consent of
responsible;

- Clinical diagnosis of bruises, sprains, trauma, muscle damage occurred in less than 24
hours or muscle pain, myofascial pain or tendinitis.

- Patients able to understand and maintain the clinical protocol.

Exclusion Criteria:

- Known hypersensitivity to components of the formulas of both the drug test as the
comparator.

- Known hypersensitivity to paracetamol.

- Location of the lesion with skin wound or irritated.

- Liver or kidney disease known.

- Pregnant or lactating women.

- Patients who require surgery or immobilization.

- Patients with fractures or rupture of the ligaments.

- Patients using anticoagulants.

- Patients with severe concomitant systemic diseases, such as cancer, diabetes, or
acquired heart disease, hematological diseases, seizure disorders, autoimmune
diseases, renal failure, severe infections, hormonal disorders and pulmonary
disorders.

- History of alcoholism or illicit drug use;

- Use of NSAIDs, corticosteroids or venoterĂ¡picos, topics or any other form of
administration.

- Conditions in the opinion of the researcher make the patient unsuitable to participate
in the study.